COVID-19 Induced Telogen Effluvium | NCT04834102

Studies
COVID-19 Induced Telogen Effluvium

NCT04834102

Sponsor

Istanbul Medeniyet University

Status

Unknown status

Last Update Posted

Apr 6, 2021Actual

Enrollment

200Estimated

Phase

Not provided

Conditions

Covid19
Telogen Effluvium
SARS-CoV Infection
Alopecia

Interventions

Blood Tests

Countries

Turkey (Türkiye)

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

Annotation Module

Unposted Annotation

Unposted Responsible Party

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Apr 2021

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jan 27, 2021Actual

Primary Completion Date

Apr 27, 2021Estimated

Completion Date

Apr 27, 2021Estimated

First Submitted Date

Apr 4, 2021

First Submission Date that Met QC Criteria

Apr 4, 2021

First Posted Date

Apr 6, 2021Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Apr 4, 2021

Last Update Posted Date

Apr 6, 2021Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

Detailed Description

Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the COVİD-19 pandemic, there is an increased number of Telogen effluvium patients.This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and correlation between the severity of covid-19 and TE.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

200Estimated

Arms/Interventions Module

Arm Groups

Not provided

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Blood Tests	Diagnostic Test	Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Hair shedding	Physical examination of hair and scalp, trichoscopy, hair pull test	3 months

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Sars-CoV-2 infection in the past year

Exclusion Criteria:

Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid dysfunction)

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Adults that are diagnosed with COVID-19 in the past year.

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Umut Mert YILDIRIM, Dr.	Contact	+905423383842		umutmertyildirim@gmail.com
Hasan AKSOY, Dr.	Contact	+905053005460		haxoil@yahoo.com

Overall Officials

Name	Affiliation	Role
Hasan AKSOY, Dr.	Istanbul Medeniyet University	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Istanbul Medeniyet University	Recruiting	Istanbul	Kadıköy	34720	Turkey (Türkiye)

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
32607303	Result	Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759/cureus.8320.
33226117	Result	Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE, Halverstam CP. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021 Jan;60(1):122-124. doi: 10.1111/ijd.15313. Epub 2020 Nov 23. No abstract available.

Type	Date	Date Unknown
Release	Sep 29, 2021
Reset	Oct 7, 2021

ID	Term
D000086382	COVID-19
D045169	Severe Acute Respiratory Syndrome
D000505	Alopecia

ID	Term
D011024	Pneumonia, Viral
D011014	Pneumonia
D012141	Respiratory Tract Infections
D007239	Infections

ID	Term
D019411	Clinical Laboratory Techniques
D019937	Diagnostic Techniques and Procedures
D003933	Diagnosis
D008919	Investigative Techniques